<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS192525</article-id><article-id pub-id-type="doi">10.1101/2023.12.02.569715</article-id><article-id pub-id-type="archive">PPR768016</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Harvesting and amplifying gene cassettes confers cross-resistance to critically important antibiotics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dulyayangkul</surname><given-names>Punyawee</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Beavis</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="fn" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Winnie WY</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Ardagh</surname><given-names>Robbie</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>Frances</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>Fergus</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Head</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author"><name><surname>Heesom</surname><given-names>Kate J.</given-names></name><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name><surname>Mounsey</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Murarik</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Reding</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Satapoomin</surname><given-names>Naphat</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>John M.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Takebayashi</surname><given-names>Yuiko</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Tooke</surname><given-names>Catherine L.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Spencer</surname><given-names>James</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Philip B.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A6">f</xref></contrib><contrib contrib-type="author"><name><surname>Avison</surname><given-names>Matthew B.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="corresp" rid="CR1">#</xref></contrib><aff id="A1"><label>a</label>School of Cellular &amp; Molecular Medicine, University of Bristol. UK</aff><aff id="A2"><label>b</label>Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok. Thailand</aff><aff id="A3"><label>c</label>North Bristol NHS Trust, Bristol. UK</aff><aff id="A4"><label>d</label>Somerset NHS Foundation Trust, Taunton. UK</aff><aff id="A5"><label>e</label>Bristol University Proteomics Facility, University of Bristol. UK</aff><aff id="A6"><label>f</label>University Hospitals Bristol and Weston NHS Foundation Trust, Bristol. UK</aff></contrib-group><author-notes><corresp id="CR1"><label>#</label>Corresponding Author: School of Cellular &amp; Molecular Medicine, University of Bristol, University Walk, Bristol, BS8 1TD, UK. <email>bimba@bristol.ac.uk</email></corresp><fn id="FN1" fn-type="present-address"><label>*</label><p id="P1">Present address, European Molecular Biology Laboratory, Heidelberg, Germany</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>05</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>04</day><month>12</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P2">Amikacin and piperacillin/tazobactam are frequent antibiotic choices to treat bloodstream infection, which is commonly fatal and most often caused by bacteria from the family <italic>Enterobacterales</italic>. Here we show that two gene cassettes located side-by-side in and ancestral integron similar to In<italic>37</italic> have been “harvested” by insertion sequence IS<italic>26</italic> as a transposon that is already globally disseminated among the <italic>Enterobacterales</italic>. This transposon encodes the enzymes AAC(6’)-Ib-cr and OXA-1, reported, respectively, as amikacin and piperacillin/tazobactam resistance mechanisms. However, by studying bloodstream infection isolates from 769 patients from, three hospitals serving a population of 1.5 million people in South West England, we show that increased enzyme production due to mutation in an IS<italic>26</italic>/In<italic>37</italic>-derived hybrid promoter or, more commonly, transposon copy number amplification is required to simultaneously remove these two key therapeutic options; in many cases leaving only the last-resort antibiotic, meropenem. These findings may help improve the accuracy of predicting piperacillin/tazobactam treatment failure, allowing stratification of patients to receive meropenem or piperacillin/tazobactam, which may improve outcome and slow the emergence of meropenem resistance.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P3">Sepsis is a life-threatening syndrome primarily resulting from bacterial bloodstream infection (BSI). It caused around 20% of deaths worldwide in 2017 (<xref ref-type="bibr" rid="R1">1</xref>). Antibiotic resistance increases mortality rates, and in 2019, approximately 1.5 million deaths globally were associated with antibiotic resistant (ABR) BSI, of which around 400,000 deaths could be directly attributed to ABR (<xref ref-type="bibr" rid="R2">2</xref>). In high income countries, BSI is primarily opportunistic, occurring when bacteria – most commonly of the species <italic>Escherichia coli</italic> – enter the blood through the urinary or gastrointestinal tracts, wounds, indwelling medical devices etc (<xref ref-type="bibr" rid="R3">3</xref>).</p><p id="P4">Rapid treatment of BSI with an effective antibiotic greatly improves outcome, so when BSI is suspected, patients are usually prescribed antibiotics before microbiological confirmation of the causative organism and its antibiotic susceptibility, which can take several days (<xref ref-type="bibr" rid="R3">3</xref>). The antibiotics of choice tend to be β-lactams, usually the penicillin/penicillinase inhibitor combination piperacillin/tazobactam, or possibly a third-generation cephalosporin (3GC) (<xref ref-type="bibr" rid="R4">4</xref>). β-lactam resistance in <italic>E. coli</italic> is primarily due to β-lactamase enzymes such as CTX-M-15 (3GC resistance) (<xref ref-type="bibr" rid="R5">5</xref>) or OXA-1 (piperacillin/tazobactam resistance) (<xref ref-type="bibr" rid="R6">6</xref>). Where β-lactams cannot be used, aminoglycoside antibiotics, either amikacin or gentamicin, are the usual alternative (<xref ref-type="bibr" rid="R4">4</xref>). In <italic>E. coli</italic>, resistance to these agents is predominantly due to aminoglycoside acetyltransferase (AAC) enzymes of the AAC(6’)-I (amikacin resistance) or AAC(<xref ref-type="bibr" rid="R3">3</xref>)-II (gentamicin resistance) types. Both inactivate their substrate by transferring an acetyl group from Acetyl-CoA to a specific position on the aminoglycoside scaffold (<xref ref-type="bibr" rid="R7">7</xref>).</p><p id="P5">OXA-1, AAC(6’)-I and AAC(<xref ref-type="bibr" rid="R3">3</xref>)-II, are encoded by gene cassettes (<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R10">10</xref>). These are promoter-less genes flanked by specific sequences used to insert them into integrons - gene cassette capture structures commonly found in bacterial genomes (<xref ref-type="bibr" rid="R11">11</xref>). A wide variety of gene cassettes exists, making integrons highly variable. Integrons provide an upstream promoter, driving expression of the gene cassettes present, and encode an integrase enzyme capable of capturing additional cassettes (<xref ref-type="bibr" rid="R11">11</xref>). Importantly, integrons are not themselves able to move between sites on DNA, e.g. from a plasmid onto the chromosome. However, integrons can be moved as part of a composite transposon, where they are flanked by two copies of the same insertion sequence (IS), which encodes a transposase enzyme that can move the transposon, potentially resulting in transposon replication (<xref ref-type="bibr" rid="R11">11</xref>).</p><p id="P6">It has been noted that piperacillin/tazobactam resistance and amikacin resistance are phenotypically linked in some <italic>E. coli</italic> populations, particularly those that are also 3GC resistant (<xref ref-type="bibr" rid="R12">12</xref>). This is important given the primacy of these agents for BSI therapy and the serious consequences of treatment failure. Our present study was initiated based on analysis of antibiotic susceptibility patterns among BSI <italic>E. coli</italic> cultured at a regional diagnostic microbiology lab serving healthcare infrastructure for a population of approximately 1.5 million people in South West England. We noted that amikacin resistance (classed as being intermediate or resistant based on standard EUCAST clinical breakpoints [13]) in BSI <italic>E. coli</italic> appears to be focussed among 3GC resistant isolates that are also piperacillin/tazobactam resistant. Here we sought the genetic reason for this association, and identified a process where contiguous pairs of gene cassettes from circulating integrons can be mobilised by an insertion sequence as part of a composite transposon. In this case, we find the transposon responsible to be globally distributed among bacteria of the family <italic>Enterobacterales,</italic> and able to amplify its copy number, causing co-resistance to critically important therapies for BSI in many healthcare settings.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Carriage of aac(6’)-Ib-cr does not always confer amikacin resistance in E. coli</title><p id="P7">In 2020, in our study region, the amikacin resistance rate, based on routine diagnostic microbiology among deduplicated isolates from 838 <italic>E. coli</italic> culture-positive BSIs (cultured from 824 individual blood samples), was 5.7%. Among 3GC-resistant <italic>E. coli</italic> isolates (defined using cefotaxime as the indicator) which caused 83 BSIs, the amikacin resistance rate was 36.1% (χ<sup>2</sup> = 157.8, p &lt; 0.00001). We were able to retrospectively recover 71 of these 3GC-resistant isolates from 2020 for whole genome sequencing (WGS) and supplemented this dataset with 69 additional 3GC-resistant BSI <italic>E. coli</italic> collected in the same region during 2018. Analysis of WGS data revealed that <italic>bla</italic><sub>CTX-M-15</sub> is the dominant cause of 3GC resistance (107/140, 76% of isolates), with 67/107 (63%) of <italic>bla</italic><sub>CTX-M-15</sub> positive isolates also carrying <italic>aac(6’)-Ib-cr</italic>, which was absent from all 33 <italic>bla</italic><sub>CTX-M-15</sub> negative 3GC-resistant isolates (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Overall, 48% of sequenced 3GC-resistant isolates carried <italic>aac(6’)-Ib-cr</italic>, which encodes a variant of AAC(6’)-I (<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R14">14</xref>) reported as an amikacin resistance mechanism (<xref ref-type="bibr" rid="R15">15</xref>). This provides a putative mechanistic explanation for the observed association between 3GC resistance and amikacin resistance among BSI <italic>E. coli</italic>. However, 14/67 (21%) of the <italic>aac(6’)-Ib-cr</italic>-positive 3GC-resistant isolates were amikacin susceptible (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). This led us to question whether carriage of <italic>aac(6’)-Ib-cr</italic> can universally confer amikacin resistance in <italic>E. coli</italic>.</p><p id="P8">We next sequenced 629 3GC-susceptible BSI <italic>E. coli</italic> from the same region, also collected in 2020. Eight were found to carry <italic>aac(6’)-Ib-cr</italic>, and of these, two (25%) were amikacin susceptible; a similar susceptibility rate to the 21% seen among 3GC-resistant <italic>aac(6’)-Ib-cr</italic>-positive isolates. One of the total of 16 sequenced amikacin-susceptible <italic>aac(6’)-Ib-cr</italic>-positive isolates identified here had a deletion spanning the -10 promoter element, the ribosome binding site and the initiation codon of <italic>aac(6’)- Ib-cr</italic>, explaining why this isolate is amikacin susceptible (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>), but in the remainder, no mutation in <italic>aac(6’)-Ib-cr</italic> or its promoter was found. Hence, in total, 15/75 (20%) of sequenced <italic>aac(6’)-Ib-cr</italic> positive bloodstream <italic>E. coli</italic> were amikacin susceptible without any explanation based on sequence. We took this as evidence that <italic>aac(6’)-Ib-cr</italic> is not always a determinant of amikacin resistance.</p></sec><sec id="S4"><title>AAC(6’)-Ib-cr is a weakened amikacin resistance determinant</title><p id="P9">In order to confirm that AAC(6’)-Ib-cr can acetylate amikacin, <italic>aac(6’)-Ib-cr</italic> was over-expressed in <italic>E. coli</italic> and the recombinant enzyme purified to homogeneity. <italic>In vitro</italic> assays demonstrated activity of AAC(6’)-Ib-cr against amikacin, albeit to a lower level than towards the structurally related aminoglycoside antibiotic kanamycin (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><p id="P10">Despite this demonstration of <italic>in vitro</italic> activity towards amikacin, recombinant <italic>E. coli</italic> carrying <italic>aac(6’)-Ib-cr</italic> ligated into a low copy number vector (<xref ref-type="bibr" rid="R16">16</xref>) remained amikacin susceptible, although the recombinant strain was kanamycin resistant, and the amikacin MIC increased four-fold over vector-only control (<xref ref-type="table" rid="T1">Table 1</xref>). Together with our <italic>in vitro</italic> results, these data indicate that AAC(6’)-Ib-cr is active towards amikacin, but, under these conditions, at a level that may not always be sufficient to cause amikacin resistance.</p><p id="P11">AAC(6’)-Ib-cr was discovered because it has two amino acid changes relative to the parent enzyme AAC(6’)-Ib, which collectively expand substrate spectrum to include some fluoroquinolones including ciprofloxacin (<xref ref-type="bibr" rid="R9">9</xref>). Site-directed mutagenesis reverting <italic>aac(6’)-Ib-cr</italic> to its parent <italic>aac(6’)-Ib</italic> in our recombinant <italic>E. coli</italic> model system resulted in a stepwise reduction in ciprofloxacin MIC, as expected, with the double, and one single, reversion mutation conferring amikacin resistance (<xref ref-type="table" rid="T1">Table 1</xref>). We conclude, therefore, that this increase in substrate spectrum of AAC(6’)-Ib-cr to encompass fluoroquinolones comes at the cost of reduced activity towards amikacin, and hence ability to confer amikacin resistance. This led to a hypothesis to explain why 20% of sequenced BSI <italic>E. coli</italic> carrying <italic>aac(6’)-Ib-cr</italic> in our region were amikacin susceptible (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>): elevated expression of this gene may be necessary to confer amikacin resistance. Importantly, <italic>aac(6’)-Ib-cr</italic> was the only aminoglycoside resistance gene in 32/38 of sequenced amikacin-resistant BSI <italic>E. coli</italic> (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Hence, if our hypothesis is correct, these data identify <italic>aac(6’)-Ib-cr</italic> over-expression as the dominant cause of amikacin resistance in BSI <italic>E. coli</italic> in our region.</p></sec><sec id="S5"><title>Capture of aac(6’)-Ib-cr by IS26 allows amikacin resistance due to promoter activation or gene copy-number amplification</title><p id="P12">In all sequenced <italic>aac(6’)-Ib-cr</italic>-positive BSI <italic>E. coli</italic> in our survey, a copy of the insertion sequence IS<italic>26</italic> was found upstream of <italic>aac(6’)-Ib-cr</italic>, and always located in the same position. The <italic>aac(6’)-Ib-cr</italic> gene cassette appears, therefore, to have been mobilised from its original location within an integron. The previously reported integron In<italic>37</italic> (<xref ref-type="bibr" rid="R17">17</xref>) carries <italic>aac(6’)-Ib-cr</italic>, the β-lactamase gene <italic>bla</italic><sub>OXA-1</sub> and the chloramphenicol acetyltransferase gene <italic>catB</italic> as its first three gene cassettes (<xref ref-type="fig" rid="F2">Fig. 2</xref>). In 66/74 <italic>aac(6’)-Ib-cr</italic> positive BSI <italic>E. coli</italic> sequenced here, these three gene cassettes are located downstream of IS<italic>26</italic> – suggesting that In<italic>37</italic> is their ancestral origin – but <italic>catB</italic> is truncated at an identical position in all by the insertion of a second copy of IS<italic>26</italic>, creating a composite transposon (<xref ref-type="fig" rid="F2">Fig. 2</xref>). In the remaining eight isolates, this second IS<italic>26</italic> copy is in a variety of positions, either truncating or entirely removing <italic>bla</italic><sub>OXA-1</sub> (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>).</p><p id="P13">IS<italic>26</italic> is known to provide an outward-facing -35 promoter element (TTGCAA) having 4/6 matches to the consensus <italic>E. coli</italic> -35 promoter element (TTGACA) (<xref ref-type="bibr" rid="R18">18</xref>). In the specific insertion seen here, this IS<italic>26</italic>-derived -35 element is found optimally positioned 17 nucleotides upstream of a CATAAT sequence that is normally present 5’ proximal to <italic>aac(6’)-Ib-cr</italic> in the integron In<italic>37</italic> and has 5/6 matches to the consensus <italic>E. coli</italic> -10 promoter element (TATAAT) (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Notably, two amikacin-resistant, <italic>aac(6’)-Ib-cr</italic> positive isolates had an identical C-T transition, strengthening this putative -10 promoter sequence and generating a perfect consensus (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Accordingly, we hypothesised that these modifications may increase <italic>aac(6’)-Ib-cr</italic> expression, potentially explaining amikacin resistance in these two isolates. LC-MS/MS proteomics confirmed that, when normalised to gene copy number and ribosomal protein abundance, this mutation increases AAC(6’)-Ib-cr production approximately 4-fold (<xref ref-type="fig" rid="F3">Fig. 3A</xref>), confirming that this IS<italic>26</italic>/In<italic>37</italic> hybrid promoter (<xref ref-type="fig" rid="F2">Fig. 2</xref>) is active, and can be made stronger by mutation.</p><p id="P14">IS<italic>26</italic>-mediated composite transposons are known to have the potential to duplicate, increasing copy number and therefore gene expression (<xref ref-type="bibr" rid="R16">16</xref>). Of the 72 sequenced <italic>aac(6’)-Ib-cr</italic> positive BSI <italic>E. coli</italic> having a wild-type IS<italic>26</italic>/In<italic>37</italic> hybrid promoter, 15 were amikacin susceptible and 57 were amikacin resistant. We hypothesised that increasing <italic>aac(6’)-Ib-cr</italic> copy number would increase gene expression, and that in the absence of promoter mutations this is the mechanism by which amikacin resistance occurs.</p><p id="P15">To test this hypothesis, the gene copy number for <italic>aac(6’)-Ib-cr</italic> was determined based on read density analysis from WGS data and isolates with differing copy numbers were selected for LC-MS/MS proteomics. A linear association was observed between AAC(6’)-Ib-cr protein abundance and gene copy number (R<sup>2</sup> = 0.76, <xref ref-type="fig" rid="F4">Fig. 4A</xref>). The single outlier is an isolate with exceptionally high <italic>aac(6’)-Ib-cr</italic> copy number, where protein abundance appears to be saturated, either in our assay, or in the cell (<xref ref-type="fig" rid="F4">Fig. 4B</xref>).</p><p id="P16">In further support of our hypothesis, we identified a strong association between AAC(6’)-Ib-cr abundance in cells and amikacin susceptibility/resistance status in those isolates subjected to proteomic analysis (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). Finally, when considering all 72 <italic>aac(6’)-Ib-cr</italic> positive BSI isolates having a wild-type IS<italic>26</italic>/In<italic>37</italic> hybrid promoter, it is apparent that our measure of gene copy number based on average read density in WGS data provides a strong predictor of amikacin susceptibility/resistance status (<xref ref-type="fig" rid="F4">Fig. 4D</xref>).</p></sec><sec id="S6"><title>Co-ordinately increased bla<sub>OXA-1</sub> expression alongside aac(6’)-Ib-cr expression confers piperacillin/tazobactam resistance</title><p id="P17">We have already observed that 66 <italic>aac(6’)-Ib-cr</italic> positive BSI isolates sequenced here carried the same IS<italic>26</italic>-mediated transposon, having fully intact <italic>aac(6’)-Ib-cr</italic> and <italic>bla</italic><sub>OXA-1</sub> genes (<xref ref-type="fig" rid="F2">Fig. 2</xref>; <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Among these isolates there was a linear correlation between the gene copy numbers of <italic>aac(6’)-Ib-cr</italic> and <italic>bla</italic><sub>OXA-1</sub>, indicative of a situation where the entire transposon is increasing in copy number (<xref ref-type="fig" rid="F5">Fig. 5A</xref>). As with AAC(6’)-Ib-cr, the activating mutation in the hybrid IS<italic>26</italic>/In<italic>37</italic> promoter increased OXA-1 production (<xref ref-type="fig" rid="F3">Fig. 3B</xref>), even though <italic>bla</italic><sub>OXA-1</sub> is the second gene cassette, and so further away from the promoter (<xref ref-type="fig" rid="F2">Fig. 2</xref>). A strong correlation was observed between <italic>bla</italic><sub>OXA-1</sub> gene copy number and OXA-1 production, as measured by proteomics – though again there was one unexpected outlier (<xref ref-type="fig" rid="F5">Fig. 5B</xref>).</p><p id="P18">OXA-1 production has previously been associated with piperacillin/tazobactam resistance (<xref ref-type="bibr" rid="R19">19</xref>). We identified, however, that as is the case for the association between AAC(6’)-Ib-cr production level and amikacin resistance, increased production of OXA-1 is necessary for piperacillin/tazobactam resistance among BSI <italic>E. coli</italic> carrying the IS<italic>26</italic>-mediated composite transposon that includes both <italic>aac(6’)-Ib-cr</italic> and <italic>bla</italic><sub>OXA-1</sub> (<xref ref-type="fig" rid="F5">Fig. 5C</xref>).</p><p id="P19">Piperacillin/tazobactam MIC is affected by multiple factors in <italic>E. coli</italic>, e.g., envelope permeability and expression of β-lactamase enzymes other than OXA-1 (<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R26">26</xref>). After excluding isolates with additional β-lactamase genes, we found that <italic>bla</italic><sub>OXA-1</sub> copy number within the IS<italic>26</italic>-mediated composite transposon (<xref ref-type="fig" rid="F2">Fig. 2</xref>) was associated with piperacillin/tazobactam susceptibility/resistance phenotype (<xref ref-type="fig" rid="F5">Fig. 5D</xref>), though this association was not as strong as that between <italic>aac(6’)-Ib-cr</italic> copy number and amikacin susceptibility/resistance status (<italic>p</italic>=0.002 vs <italic>p</italic>=0.0006; <xref ref-type="fig" rid="F5">Fig. 5D</xref>; <xref ref-type="fig" rid="F4">Fig. 4D</xref>), likely because piperacillin/tazobactam resistance is multi-factorial, whereas amikacin resistance in <italic>E. coli</italic> is almost exclusively caused by an aminoglycoside modifying enzyme (<xref ref-type="bibr" rid="R15">15</xref>).</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P20">We have previously reported linkage between <italic>bla</italic><sub>CTX-M-15</sub>, <italic>bla</italic><sub>OXA-1</sub> and <italic>aac(6’)-Ib-cr</italic> carriage in urinary <italic>E. coli</italic> from our region in South West England (<xref ref-type="bibr" rid="R27">27</xref>), here confirmed among BSI isolates. Recently, a genomic survey of urinary <italic>E. coli</italic> isolated in the U.S. also reported linkage between <italic>bla</italic><sub>CTX-M-15</sub>, <italic>bla</italic><sub>OXA-1</sub> and <italic>aac(6’)-Ib-cr</italic> (<xref ref-type="bibr" rid="R12">12</xref>). The authors noted that <italic>aac(6’)-Ib-cr</italic> carriage was not universally associated with amikacin resistance, as reported here among BSI <italic>E. coli</italic> in our region (<xref ref-type="bibr" rid="R12">12</xref>). Moreover, the authors speculated that <italic>aac(6’)-Ib-cr</italic>-positive amikacin-resistant isolates carried additional amikacin resistance mechanisms, not present in the <italic>aac(6’)-Ib-cr</italic>-positive amikacin susceptible isolates, but could not identify these additional mechanisms from WGS data (<xref ref-type="bibr" rid="R12">12</xref>). Here we show that <italic>aac(6’)-Ib-cr</italic> gene amplification provides the likely molecular explanation for this switch from amikacin susceptibility to resistance, at least in our region and possibly elsewhere.</p><p id="P21">IS<italic>26</italic> is renowned as a pathway to composite transposon formation and mobilisation (<xref ref-type="bibr" rid="R18">18</xref>), first coming to prominence as the mechanism by which <italic>bla</italic><sub>SHV</sub> was mobilised from the <italic>Klebsiella pneumoniae</italic> chromosome prior to mutation into a group of extended spectrum β-lactamase (ESBL) variants, which then spread globally as a 3GC resistance mechanism in the <italic>Enterobacterales</italic> (<xref ref-type="bibr" rid="R28">28</xref>). Recently, IS<italic>26</italic> was shown also to have captured <italic>bla</italic><sub>TEM-1</sub>, the most common acquired amoxicillin resistance mechanism in <italic>E. coli</italic>. The copy number of the resultant composite transposon can be amplified by IS<italic>26</italic>, increasing TEM-1 production and the MICs of various amino-penicillin/β-lactamase inhibitor combinations, including piperacillin/tazobactam (<xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R25">25</xref>). Furthermore, in an <italic>in vitro</italic> mutant selection study using a model <italic>E. coli</italic> system and recombinant plasmid, it has recently been reported that <italic>bla</italic><sub>OXA-1</sub> copy number amplification was associated with evolution towards piperacillin/tazobactam resistance in the laboratory, and was driven by IS<italic>26</italic> (<xref ref-type="bibr" rid="R29">29</xref>).</p><p id="P22">Here we have identified another IS<italic>26</italic> mobilisation event with significant clinical implications, generating a 3699-nucleotide composite transposon (<xref ref-type="fig" rid="F2">Fig. 2</xref>). The <italic>aac(6’)-Ib-cr</italic> variant gene cassette was first found in a clinical isolate collected in 2003, and was shown to encode an enzyme capable of acetylating ciprofloxacin (<xref ref-type="bibr" rid="R9">9</xref>). Whilst this gene cannot confer ciprofloxacin resistance alone (<xref ref-type="bibr" rid="R16">16</xref>), it does contribute to survival in the presence of the drug even in bacteria where ciprofloxacin resistance is caused by target site mutations (<xref ref-type="bibr" rid="R30">30</xref>).</p><p id="P23">Likely because this variant is relatively recently emerged, <italic>aac(6’)-Ib-cr</italic> is found in only 17 INTEGRALL integron database entries out of a total of 336 integrons carrying <italic>aac(6’)-Ib-variants</italic> (<xref ref-type="bibr" rid="R31">31</xref>). Furthermore, in 11/17 integrons on this database, <italic>aac(6’)-Ib-cr</italic> is the first gene cassette, being closest to the integron promoter (gene cassettes are promoter-less [11]) followed by <italic>bla</italic><sub>OXA-1</sub> and <italic>catB3</italic> in a polycistronic structure first seen in the integron In<italic>37</italic> (<xref ref-type="bibr" rid="R17">17</xref>) (<xref ref-type="fig" rid="F2">Fig. 2</xref>). The predominance of this arrangement appears to have provided the opportunity for IS<italic>26</italic> to mobilise two critically important resistance genes together, providing an upstream hybrid promoter and the potential for <italic>aac(6’)-Ib-cr</italic> and <italic>bla</italic><sub>OXA-1</sub> to be hyper-expressed together. This can be either due to hybrid promoter strengthening mutation (<xref ref-type="fig" rid="F3">Fig. 3</xref>) or gene copy number amplification (<xref ref-type="fig" rid="F4">Fig. 4B</xref>; <xref ref-type="fig" rid="F5">5B</xref>). Both outcomes were seen in clinical isolates in this study, but copy number amplification was more common. The result is a phenotype compromising two therapies for BSI, piperacillin/tazobactam and amikacin, that are commonly used where the causative pathogen is already 3GC-resistant, or where clinicians wish to spare 3GC use for other reasons.</p><p id="P24">Using blastn, an identical 3699 nucleotide IS<italic>26</italic>-<italic>aac(6’)-Ib-cr-bla</italic><sub>OXA-1</sub>-IS<italic>26</italic> composite transposon (<xref ref-type="fig" rid="F2">Fig. 2</xref>) was detected in 714 NCBI database entries (10th June 2023), including 221 <italic>E. coli</italic> and 434 <italic>Klebsiella</italic> spp. The first published report referring to one of these database entries was in 2010 (<xref ref-type="bibr" rid="R32">32</xref>). This is extremely concerning because, whilst information in the database does not make it possible to confirm or deny copy number amplification for these strains, it is clear that the raw materials required for coordinated loss of piperacillin/tazobactam and amikacin from the therapeutic armamentarium are already widely and globally disseminated.</p><p id="P25">There has been some interest in the utility of piperacillin/tazobactam and amikacin as combination therapy, and pharmacodynamics comparable to meropenem have been reported against 3GC-resistant <italic>E. coli</italic> carrying <italic>bla</italic><sub>CTX-M-15</sub>, <italic>bla</italic><sub>OXA-1</sub> and <italic>aac(6’)-Ib-cr</italic> (<xref ref-type="bibr" rid="R33">33</xref>). It is entirely possible that the two agents could work additively (e.g., by piperacillin/tazobactam increasing amikacin penetration) but our work reported here suggests potential problems. We do not know the ceiling of copy number amplification for the transposon identified here, or the level of resultant piperacillin/tazobactam and amikacin MICs. Therefore, thorough testing of isolates with demonstrated transposon copy number amplification is advised during future validation of this combination.</p><p id="P26">In isolates from our region resistant to piperacillin/tazobactam and amikacin, few therapeutic options remain: 3GCs, gentamicin and meropenem being the most widely used. Of 53 sequenced amikacin-resistant bloodstream isolates carrying the transposon identified here, 94% were 3GC-resistant and 34% were gentamicin-resistant. This compares with 3GC- and gentamicin-resistance rates of 9.7% and 8.9%, respectively, among all BSI isolates collected in our region in 2020. In contrast, 100% of the transposon-carrying isolates in our study were susceptible to meropenem, widely considered a last resort antibiotic.</p><p id="P27">This resonates with findings from the Australasian MERINO study that piperacillin/tazobactam cannot be considered non-inferior to meropenem against 3GC-resistant (predominantly CTX-M-producing) but piperacillin/tazobactam-susceptible (based on diagnostic laboratory tests) <italic>E. coli</italic> and <italic>K. pneumoniae</italic> BSI; and in consequence that use of piperacillin/tazobactam as a meropenem-sparing therapy could not be supported (<xref ref-type="bibr" rid="R34">34</xref>). However, a more recent trial suggests that piperacillin/tazobactam is non-inferior to meropenem when BSI is caused by 3GC-resistant <italic>E. coli</italic> in geographical regions where <italic>bla</italic><sub>OXA-1</sub> is uncommon (<xref ref-type="bibr" rid="R35">35</xref>). One possible reason for this is that there can be considerable diagnostic uncertainty about piperacillin/tazobactam susceptibility in OXA-1-producing isolates (<xref ref-type="bibr" rid="R36">36</xref>), though it is clear from a number of clinical surveillance studies that carriage of <italic>bla</italic><sub>OXA-1</sub> is associated with elevated piperacillin/tazobactam MIC (<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R37">37</xref>). Our work reported here suggests that elevated <italic>bla</italic><sub>OXA-1</sub> expression, rather than simply its presence, is associated with piperacillin/tazobactam resistance. It may be that this elevated expression is not detected by some or all currently available clinical tests for piperacillin/tazobactam susceptibility. It may be, also, that consideration of the amikacin susceptible/resistant phenotype in these isolates, which we have shown here is strongly associated with <italic>aac(6’)-Ib-cr,</italic> and so <italic>bla</italic><sub>OXA-1</sub>, expression (<xref ref-type="fig" rid="F4">Fig 4</xref>, <xref ref-type="fig" rid="F5">Fig 5</xref>) will be useful as a way to predict potential piperacillin/tazobactam treatment failure, even if clinical diagnostics indicate piperacillin/tazobactam susceptibility. Hence knowledge of amikacin susceptibility may be a way of stratifying patients to receive piperacillin/tazobactam or meropenem, improving treatment outcomes whilst sparing meropenem use until there is no other viable option.</p></sec><sec id="S8"><title>Experimental</title><sec id="S9"><title>Isolates, Antibiotic Susceptibility Testing and Ethics Statement</title><p id="P28">Isolates were collected from patients with BSI at three hospitals: Bristol Royal Infirmary, Southmead Hospital and the Royal United Hospital, Bath; collectively serving a population of approximately 1.2 million people in the South West of England. Blood samples were collected throughout 2018 and 2020 and processed for routine diagnostic microbiology at a single laboratory, Severn Pathology. Culture-positive samples were further processed by Gram stain, and bacterial species identified using MALDI-TOF mass spectrometry. Antibiotic susceptibility profiles were determined using disc diffusion directly from culture positive blood (piperacillin/tazobactam only) or using Vitek following initial culture on agar (all other agents). Susceptibility/resistance was defined using EUCAST breakpoints (<xref ref-type="bibr" rid="R13">13</xref>) at the time of isolation; where “intermediate” breakpoints were in use, intermediate isolates were defined as resistant. The result for cefotaxime was used to define 3GC susceptibility/resistance. Isolates were deduplicated by patient and antibiotic susceptibility profile using a &gt;7 day re-sampling limit. This project is not part of a trial or wider clinical study requiring ethical review. All bacterial isolates came from routine diagnostic samples and no patient data was recorded or used.</p></sec><sec id="S10"><title>WGS and data analysis</title><p id="P29">Genomes were sequenced by MicrobesNG (Birmingham, UK) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic v0.39 (<xref ref-type="bibr" rid="R38">38</xref>) and assembled into contigs using SPAdes (<xref ref-type="bibr" rid="R39">39</xref>) v3.13.0 (<ext-link ext-link-type="uri" xlink:href="http://cab.spbu.ru/software/spades/">http://cab.spbu.ru/software/spades/</ext-link>). and contigs were annotated using Prokka v1.14.5 (<xref ref-type="bibr" rid="R40">40</xref>). The presence of resistance genes was determined with ABRicate v1.0.1 using the ResFinder v2.1 database (<xref ref-type="bibr" rid="R41">41</xref>). Gene copy number was determined using a bespoke pipeline, Hound (<xref ref-type="bibr" rid="R42">42</xref>), where raw reads were mapped against the assembled genome using the Burrows-Wheeler aligner BWA (<xref ref-type="bibr" rid="R43">43</xref>) and the resulting alignments were processed with SAMtools to extract read depth (<xref ref-type="bibr" rid="R44">44</xref>).</p></sec><sec id="S11"><title>Cloning and mutagenesis of aac(6’)-Ib-cr</title><p id="P30">The <italic>aac(6</italic>′<italic>)-Ib-cr</italic> gene was synthesized (Eurofins Genomics) to include its native promoter from 5-‘GAGCAAACGATCAATGCG to AAGCCTAGCCAATTTGCTAGG-3’, as presented in Genbank accession number JF775514.1, and ligated into the pEX-K4 cloning vector (Eurofins). The insert was subcloned into the low copy number plasmid pSU18 and recombinants used to transform <italic>E. coli</italic> XL10-Gold (Stratagene) to chloramphenicol resistance (30 mg/L). Site directed mutagenesis was performed using the Quick-Change Lightning kit (Agilent Technologies) and primers “R-W mutant” (5’-CCGTAACCACCCCAGATGGTCCAGCCGTG-3’) and “Y-D mutant” (5’-GGAAGCGGGGACGGATGGTGGGAAGAA-3’).</p></sec><sec id="S12"><title>Overexpression and purification of recombinant AAC(6’)-Ib-cr</title><p id="P31">The <italic>aac(6</italic>′<italic>)-Ib-cr</italic> open reading frame was amplified from the synthetic gene template using primers (5’-AAGTTCTGTTTCAGGGCCCGAGCAACGCAAAAACAAAGTTAG-3’ and 5’-ATGGTCTAGAAAGCTTTAGGCATCACTGCGTGTTC-3’) and subcloned into the T7 expression vector pOPINF (<xref ref-type="bibr" rid="R45">45</xref>) using the InFusion recombinase system (Takara Bio) according to manufacturer’s instructions. The integrity of the resulting construct was confirmed by sequencing (Eurofins Genomics). The recombinant <italic>aac(6’)-Ib-cr</italic>:pOPINF vector was used to transform the <italic>E. coli</italic> T7 expression strain SOLUBL21 (AMS Biotechnology), a single colony was picked and grown overnight in LB growth medium and the resulting culture used for 1% inoculation of 8 x 500 mL of 2 x YT in 2L conical flasks grown at 37 °C with 180 rpm shaking. When absorbance at 600 nm reached 0.6, expression was induced with 0.5 mM IPTG, the temperature was reduced to 18°C and the culture was grown for a further 18 h. Cells were harvested by centrifugation (Beckman-Coulter Avanti J-26XP, 6500 x g), the supernatant was discarded and pellet resuspended in buffer A (50 mM Tris pH 7.8, 150 mM NaCl, 10 mM Imidazole). Subsequent steps were carried out at 4°C. The cell suspension was homogenised and sonicated (Sonics<sup>®</sup> Vibra-Cell™ VC-505TM, Sonics &amp; Materials Inc., Newton, CT, USA), 1 s pulse mode, 64% intensity) before ultracentrifugation at 100,000 x g (Beckman Coulter Optima L-80 XP) for 45 min to remove insoluble material. The supernatant was applied to a 5 mL HisTrap Ni-NTA column (Cytiva Life Sciences) pre-equilibrated in buffer A, the column was washed until absorbance returned to base line and bound proteins eluted in buffers B (50 mM Tris pH 7.8, 150 mM NaCl, 20 mM imidazole) and C (50 mM Tris pH 7.8, 150 mM NaCl, 500 mM imidazole). Fractions adjudged, on the basis of inspection of SDS-PAGE gels, to contain AAC(6’)-Ib-cr were pooled, concentrated by centrifugal filtration (Sartorius) and loaded onto a Superdex-S75 column (Cytiva Life Sciences) pre-equilibrated with buffer D (50 mM Tris pH 7.8, 150 mM NaCl, 5 mM dithiothreitol (DTT)). Fractions containing AAC(6’)-Ib-cr were identified from SDS-PAGE gels and pooled.</p></sec><sec id="S13"><title>Measurement of enzyme activity</title><p id="P32">Acetylation of aminoglycoside antibiotics was monitored using the chromogenic 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) assay to detect the free thiol generated on donation of an acetyl group from acetyl-CoA. Reaction rates were measured in UV-star half area clear 96-well microplates (Greiner Bio-One) using a BMG Labtech Clariostar microplate reader. Assays were carried out in triplicate, with a final volume of 100 μl/well, in 50 mM MES pH 6.1 supplemented with 500 µg/mL Bovine Serum Albumin, 2 mM DTNB, 0.1 mM acetyl-CoA, 100 nM purified AAC(6’)-Ib-cr and varying concentrations of the aminoglycoside substrates kanamycin B or amikacin. Enzyme activities were calculated by monitoring absorbance at 412 nm over time using a molar absorption coefficient of 13,600 M<sup>-1</sup>.cm<sup>-1</sup>.</p></sec><sec id="S14"><title>Proteomic analysis</title><p id="P33">A volume of 1 mL of overnight liquid culture was transferred to 50 mL of fresh Cation Adjusted Muller Hinton Broth and incubated at 37°C until an optical density at 600 nm of 0.5 to 0.6. Samples were centrifuged at 4,000 rpm for 10 min at 4°C and the supernatants discarded. Cells were resuspended into 35 mL of 30 mM Tris-HCl, pH 8 and broken by sonication using a cycle of 1 s on, 1 s off for 3 min at amplitude of 63% using a Sonics Vibra-Cell VC-505TM. Non-lysed cells were pelleted by centrifugation at 8,000 rpm (Sorvall RC5B Plus using an SS-34 rotor) for 15 min at 4°C. The supernatant was used as a direct source of protein for analysis. LC-MS/MS was performed and data analysed as described previously (<xref ref-type="bibr" rid="R46">46</xref>,<xref ref-type="bibr" rid="R47">47</xref>) using 5 μg of protein for each run. Analysis was performed in triplicate, each from a separate batch of cells. Abundance for each test protein in a sample was normalized relative to the average abundance of ribosomal proteins in the same sample.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Information</label><media xlink:href="EMS192525-supplement-Supplementary_Information.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d159aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S15"><title>Acknowledgements</title><p>This work was funded by Medical Research Council grant MR/T005408/1 (to P.B.W. and M.B.A), by grants MR/N013646/1 (to M.B.A. and K.J.H.), MR/S004769/1 and NE/N01961X/1 (to M.B.A.) from the Antimicrobial Resistance Cross Council Initiative supported by the seven UK research councils and the National Institute for Health Research (NIHR), and by grant 82459 (to M.B.A.) from the Welsh Government Rural Communities - Rural Development Programme 2014-2020 supported by the European Union and the Welsh Government. W.W.Y.L. received a scholarship from the Medical Research Foundation National PhD Training Program in Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO). Clinical training fellowships were funded by the Wellcome Trust (to F.E. and F.H) and NIHR (to I.H.). N.S. was supported by a postgraduate scholarship from the University of Bristol. We are grateful to laboratory staff at Severn Pathology, North Bristol NHS Trust, for collecting the bloodstream isolates, and to Dr Jacqueline Findlay, formerly of the School of Cellular &amp; Molecular Medicine, University of Bristol, for preparing the 2018 isolates for sequencing. WGS was performed by MicrobesNG, Birmingham, UK.</p></ack><ref-list><ref id="R1"><label>(1)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Agesa</surname><given-names>KM</given-names></name><name><surname>Shackelford</surname><given-names>KA</given-names></name><name><surname>Tsoi</surname><given-names>D</given-names></name><name><surname>Kievlan</surname><given-names>DR</given-names></name><name><surname>Colombara</surname><given-names>DV</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Kissoon</surname><given-names>N</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Fleischmann-Struzek</surname><given-names>C</given-names></name><etal/></person-group><article-title>Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study</article-title><source>Lancet (London, England)</source><year>2020</year><volume>95</volume><fpage>200</fpage><lpage>11</lpage><pub-id pub-id-type="pmcid">PMC6970225</pub-id><pub-id pub-id-type="pmid">31954465</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32989-7</pub-id></element-citation></ref><ref id="R2"><label>(2)</label><element-citation publication-type="journal"><collab>Antimicrobial Resistance Collaborators</collab><article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage></element-citation></ref><ref id="R3"><label>(3)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>WV</given-names></name><name><surname>Rieg</surname><given-names>S</given-names></name></person-group><article-title>Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens</article-title><source>Clin Microbiol Infect</source><year>2020</year><volume>26</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">31712069</pub-id></element-citation></ref><ref id="R4"><label>(4)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MM</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Rogers</surname><given-names>BA</given-names></name><name><surname>Harris</surname><given-names>PNA</given-names></name><name><surname>Sime</surname><given-names>FB</given-names></name></person-group><article-title>Current and Emerging Treatment Options for Multidrug Resistant Escherichia coli Urosepsis: A Review</article-title><source>Antibiotics (Basel)</source><year>2022</year><volume>11</volume><elocation-id>1821</elocation-id><pub-id pub-id-type="pmcid">PMC9774639</pub-id><pub-id pub-id-type="pmid">36551478</pub-id><pub-id pub-id-type="doi">10.3390/antibiotics11121821</pub-id></element-citation></ref><ref id="R5"><label>(5)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanheira</surname><given-names>M</given-names></name><name><surname>Simner</surname><given-names>PJ</given-names></name><name><surname>Bradford</surname><given-names>PA</given-names></name></person-group><article-title>Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection</article-title><source>JAC Antimicrob Resist</source><year>2021</year><volume>3</volume><elocation-id>dlab092</elocation-id><pub-id pub-id-type="pmcid">PMC8284625</pub-id><pub-id pub-id-type="pmid">34286272</pub-id><pub-id pub-id-type="doi">10.1093/jacamr/dlab092</pub-id></element-citation></ref><ref id="R6"><label>(6)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livermore</surname><given-names>DM</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Cleary</surname><given-names>P</given-names></name><name><surname>Hopkins</surname><given-names>KL</given-names></name><name><surname>Toleman</surname><given-names>MA</given-names></name><name><surname>Wareham</surname><given-names>DW</given-names></name><name><surname>Wiuff</surname><given-names>C</given-names></name><name><surname>Doumith</surname><given-names>M</given-names></name><name><surname>Woodford</surname><given-names>N</given-names></name></person-group><article-title>OXA-1 β-lactamase and resistance to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli</article-title><source>J Antimicrob Chemother</source><year>2019</year><volume>74</volume><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">30388219</pub-id></element-citation></ref><ref id="R7"><label>(7)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>MS</given-names></name><name><surname>Tolmasky</surname><given-names>ME</given-names></name></person-group><article-title>Aminoglycoside modifying enzymes</article-title><source>Drug Resist Updat</source><year>2010</year><volume>13</volume><fpage>151</fpage><lpage>71</lpage><pub-id pub-id-type="pmcid">PMC2992599</pub-id><pub-id pub-id-type="pmid">20833577</pub-id><pub-id pub-id-type="doi">10.1016/j.drup.2010.08.003</pub-id></element-citation></ref><ref id="R8"><label>(8)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>J</given-names></name><name><surname>Capitano</surname><given-names>L</given-names></name><name><surname>Nuñez</surname><given-names>L</given-names></name><name><surname>Castro</surname><given-names>D</given-names></name><name><surname>Sierra</surname><given-names>JM</given-names></name><name><surname>Hatha</surname><given-names>M</given-names></name><name><surname>Borrego</surname><given-names>JJ</given-names></name><name><surname>Vila</surname><given-names>J</given-names></name></person-group><article-title>Mechanisms of resistance to ampicillin, chloramphenicol and quinolones in multiresistant Salmonella typhimurium strains isolated from fish</article-title><source>J Antimicrob Chemother</source><year>1999</year><volume>43</volume><fpage>699</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">10382892</pub-id></element-citation></ref><ref id="R9"><label>(9)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robicsek</surname><given-names>A</given-names></name><name><surname>Strahilevitz</surname><given-names>J</given-names></name><name><surname>Jacoby</surname><given-names>GA</given-names></name><name><surname>Macielag</surname><given-names>M</given-names></name><name><surname>Abbanat</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Hooper</surname><given-names>DC</given-names></name></person-group><article-title>Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>83</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16369542</pub-id></element-citation></ref><ref id="R10"><label>(10)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandvang</surname><given-names>D</given-names></name><name><surname>Aarestrup</surname><given-names>FM</given-names></name></person-group><article-title>Characterization of aminoglycoside resistance genes and class 1 integrons in porcine and bovine gentamicin-resistant Escherichia coli</article-title><source>Microb Drug Resist</source><year>2000</year><volume>6</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10868804</pub-id></element-citation></ref><ref id="R11"><label>(11)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillings</surname><given-names>MR</given-names></name></person-group><article-title>Integrons: past, present, and future</article-title><source>Microbiol Mol Biol Rev</source><year>2014</year><volume>78</volume><fpage>257</fpage><lpage>77</lpage><pub-id pub-id-type="pmcid">PMC4054258</pub-id><pub-id pub-id-type="pmid">24847022</pub-id><pub-id pub-id-type="doi">10.1128/MMBR.00056-13</pub-id></element-citation></ref><ref id="R12"><label>(12)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>N</given-names></name><name><surname>Belmont</surname><given-names>CR</given-names></name><name><surname>Tarlton</surname><given-names>NJ</given-names></name><name><surname>Allegretti</surname><given-names>YH</given-names></name><name><surname>Adams-Sapper</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>YY</given-names></name><name><surname>Borges</surname><given-names>CA</given-names></name><name><surname>Frazee</surname><given-names>BW</given-names></name><name><surname>Florence-Petrovic</surname><given-names>D</given-names></name><name><surname>Hufana</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetic Predictive Factors for Nonsusceptible Phenotypes and Multidrug Resistance in Expanded-Spectrum Cephalosporin-Resistant Uropathogenic Escherichia coli from a Multicenter Cohort: Insights into the Phenotypic and Genetic Basis of Coresistance</article-title><source>mSphere</source><year>2022</year><volume>7</volume><elocation-id>e0047122</elocation-id><pub-id pub-id-type="pmcid">PMC9769571</pub-id><pub-id pub-id-type="pmid">36377882</pub-id><pub-id pub-id-type="doi">10.1128/msphere.00471-22</pub-id></element-citation></ref><ref id="R13"><label>(13)</label><element-citation publication-type="web"><date-in-citation>accessed June 2023</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf</ext-link></comment></element-citation></ref><ref id="R14"><label>(14)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fihman</surname><given-names>V</given-names></name><name><surname>Lartigue</surname><given-names>MF</given-names></name><name><surname>Jacquier</surname><given-names>H</given-names></name><name><surname>Meunier</surname><given-names>F</given-names></name><name><surname>Schnepf</surname><given-names>N</given-names></name><name><surname>Raskine</surname><given-names>L</given-names></name><name><surname>Riahi</surname><given-names>J</given-names></name><name><surname>Sanson-le Pors</surname><given-names>MJ</given-names></name><name><surname>Berçot</surname><given-names>B</given-names></name></person-group><article-title>Appearance of aac(6’)-Ib-cr gene among extended-spectrum beta-lactamase-producing Enterobacteriaceae in a French hospital</article-title><source>J Infect</source><year>2008</year><volume>56</volume><fpage>454</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18440645</pub-id></element-citation></ref><ref id="R15"><label>(15)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>MS</given-names></name><name><surname>Tolmasky</surname><given-names>ME</given-names></name></person-group><article-title>Amikacin: Uses, Resistance, and Prospects for Inhibition</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>2267</elocation-id><pub-id pub-id-type="pmcid">PMC5889950</pub-id><pub-id pub-id-type="pmid">29257114</pub-id><pub-id pub-id-type="doi">10.3390/molecules22122267</pub-id></element-citation></ref><ref id="R16"><label>(16)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan Nur Ismah</surname><given-names>WAK</given-names></name><name><surname>Takebayashi</surname><given-names>Y</given-names></name><name><surname>Findlay</surname><given-names>J</given-names></name><name><surname>Heesom</surname><given-names>KJ</given-names></name><name><surname>Jiménez-Castellanos</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>L</given-names></name><name><surname>Bowker</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>OM</given-names></name><name><surname>MacGowan</surname><given-names>AP</given-names></name><name><surname>Avison</surname><given-names>MB</given-names></name></person-group><article-title>Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><elocation-id>e01814-17</elocation-id><pub-id pub-id-type="pmcid">PMC5826109</pub-id><pub-id pub-id-type="pmid">29263066</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01814-17</pub-id></element-citation></ref><ref id="R17"><label>(17)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>JH</given-names></name><name><surname>Jacoby</surname><given-names>GA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Hooper</surname><given-names>DC</given-names></name></person-group><article-title>Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China</article-title><source>Antimicrob Agents Chemother</source><year>2003</year><volume>47</volume><fpage>2242</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC161834</pub-id><pub-id pub-id-type="pmid">12821475</pub-id><pub-id pub-id-type="doi">10.1128/AAC.47.7.2242-2248.2003</pub-id></element-citation></ref><ref id="R18"><label>(18)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varani</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Siguier</surname><given-names>P</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Chandler</surname><given-names>M</given-names></name></person-group><article-title>The IS6 family, a clinically important group of insertion sequences including IS26</article-title><source>Mob DNA</source><year>2021</year><volume>12</volume><fpage>11</fpage><pub-id pub-id-type="pmcid">PMC7986276</pub-id><pub-id pub-id-type="pmid">33757578</pub-id><pub-id pub-id-type="doi">10.1186/s13100-021-00239-x</pub-id></element-citation></ref><ref id="R19"><label>(19)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkty</surname><given-names>A</given-names></name><name><surname>Karlowsky</surname><given-names>JA</given-names></name><name><surname>Lagacé-Wiens</surname><given-names>PRS</given-names></name><name><surname>Golden</surname><given-names>AR</given-names></name><name><surname>Baxter</surname><given-names>MR</given-names></name><name><surname>Denisuik</surname><given-names>AJ</given-names></name><name><surname>McCracken</surname><given-names>M</given-names></name><name><surname>Mulvey</surname><given-names>MR</given-names></name><name><surname>Adam</surname><given-names>HJ</given-names></name><name><surname>Zhanel</surname><given-names>GG</given-names></name></person-group><article-title>Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007-18)</article-title><source>JAC Antimicrob Resist</source><year>2022</year><volume>4</volume><elocation-id>dlac027</elocation-id><pub-id pub-id-type="pmcid">PMC8935204</pub-id><pub-id pub-id-type="pmid">35321395</pub-id><pub-id pub-id-type="doi">10.1093/jacamr/dlac027</pub-id></element-citation></ref><ref id="R20"><label>(20)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>T</given-names></name><name><surname>Heinz</surname><given-names>E</given-names></name><name><surname>van Aartsen</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>P</given-names></name><name><surname>Corless</surname><given-names>C</given-names></name><name><surname>Fraser</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>CT</given-names></name><name><surname>Bulgasim</surname><given-names>I</given-names></name><name><surname>Cuevas</surname><given-names>LE</given-names></name><name><surname>Parry</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types</article-title><source>Microb Genom</source><year>2022</year><volume>8</volume><elocation-id>000789</elocation-id><pub-id pub-id-type="pmcid">PMC9453079</pub-id><pub-id pub-id-type="pmid">35404783</pub-id><pub-id pub-id-type="doi">10.1099/mgen.0.000789</pub-id></element-citation></ref><ref id="R21"><label>(21)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>C</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Yokota</surname><given-names>SI</given-names></name></person-group><article-title>Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><elocation-id>105919</elocation-id><pub-id pub-id-type="pmid">32062000</pub-id></element-citation></ref><ref id="R22"><label>(22)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurpiel</surname><given-names>PM</given-names></name><name><surname>Hanson</surname><given-names>ND</given-names></name></person-group><article-title>Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli</article-title><source>J Antimicrob Chemother</source><year>2012</year><volume>67</volume><fpage>339</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">22117029</pub-id></element-citation></ref><ref id="R23"><label>(23)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schechter</surname><given-names>LM</given-names></name><name><surname>Creely</surname><given-names>DP</given-names></name><name><surname>Garner</surname><given-names>CD</given-names></name><name><surname>Shortridge</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hanson</surname><given-names>BM</given-names></name><name><surname>Sodergren</surname><given-names>E</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name><name><surname>Dunne</surname><given-names>WM</given-names><suffix>Jr</suffix></name><name><surname>van Belkum</surname><given-names>A</given-names></name><etal/></person-group><article-title>Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>18</fpage><elocation-id>e00583</elocation-id><pub-id pub-id-type="pmcid">PMC5915731</pub-id><pub-id pub-id-type="pmid">29691340</pub-id><pub-id pub-id-type="doi">10.1128/mBio.00583-18</pub-id></element-citation></ref><ref id="R24"><label>(24)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>KH</given-names></name><name><surname>Andreasen</surname><given-names>MR</given-names></name><name><surname>Pedersen</surname><given-names>MS</given-names></name><name><surname>Westh</surname><given-names>H</given-names></name><name><surname>Jelsbak</surname><given-names>L</given-names></name><name><surname>Schønning</surname><given-names>K</given-names></name></person-group><article-title>Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1</article-title><source>J Antimicrob Chemother</source><year>2019</year><volume>74</volume><fpage>3179</fpage><lpage>3183</lpage><pub-id pub-id-type="pmid">31411684</pub-id></element-citation></ref><ref id="R25"><label>(25)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>ATM</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>P</given-names></name><name><surname>Parry</surname><given-names>CM</given-names></name><name><surname>Corless</surname><given-names>C</given-names></name><name><surname>van Aartsen</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>A</given-names></name><name><surname>Bulgasim</surname><given-names>I</given-names></name><name><surname>Fraser</surname><given-names>AJ</given-names></name><name><surname>Adams</surname><given-names>ER</given-names></name><name><surname>Roberts</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><elocation-id>4915</elocation-id><pub-id pub-id-type="pmcid">PMC7530762</pub-id><pub-id pub-id-type="pmid">33004811</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-18668-2</pub-id></element-citation></ref><ref id="R26"><label>(26)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gálvez-Benítez</surname><given-names>L</given-names></name><name><surname>de la Rosa</surname><given-names>JMO</given-names></name><name><surname>Rodriguez-Villodres</surname><given-names>A</given-names></name><name><surname>Casimiro-Soriguer</surname><given-names>CS</given-names></name><name><surname>Molina-Panadero</surname><given-names>I</given-names></name><name><surname>Alvarez-Marin</surname><given-names>R</given-names></name><name><surname>Bonnin</surname><given-names>RA</given-names></name><name><surname>Naas</surname><given-names>T</given-names></name><name><surname>Pachón</surname><given-names>J</given-names></name><name><surname>Cisneros</surname><given-names>JM</given-names></name><name><surname>Lepe</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Role of blaTEM and OmpC in the piperacillin-tazobactam resistance evolution by E coli in patients with complicated intra-abdominal infection</article-title><source>J Infect S</source><year>2023</year><elocation-id>S0163-4453:00377-8</elocation-id><pub-id pub-id-type="pmid">37442373</pub-id></element-citation></ref><ref id="R27"><label>(27)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mounsey</surname><given-names>O</given-names></name><name><surname>Schubert</surname><given-names>H</given-names></name><name><surname>Findlay</surname><given-names>J</given-names></name><name><surname>Morley</surname><given-names>K</given-names></name><name><surname>Puddy</surname><given-names>EF</given-names></name><name><surname>Gould</surname><given-names>VC</given-names></name><name><surname>North</surname><given-names>P</given-names></name><name><surname>Bowker</surname><given-names>KE</given-names></name><name><surname>Williams</surname><given-names>OM</given-names></name><name><surname>Williams</surname><given-names>PB</given-names></name><name><surname>Barrett</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region</article-title><source>J Antimicrob Chemother</source><year>2021</year><volume>76</volume><fpage>3144</fpage><lpage>3150</lpage><pub-id pub-id-type="pmcid">PMC8598280</pub-id><pub-id pub-id-type="pmid">34450630</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkab310</pub-id></element-citation></ref><ref id="R28"><label>(28)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>PJ</given-names></name><name><surname>Avison</surname><given-names>MB</given-names></name></person-group><article-title>Evolutionary mapping of the SHV beta-lactamase and evidence for two separate IS26-dependent blaSHV mobilization events from the Klebsiella pneumoniae chromosome</article-title><source>J Antimicrob Chemother</source><year>2004</year><volume>54</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15163647</pub-id></element-citation></ref><ref id="R29"><label>(29)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajer</surname><given-names>F</given-names></name><name><surname>Allander</surname><given-names>L</given-names></name><name><surname>Karlsson</surname><given-names>PA</given-names></name><name><surname>Sandegren</surname><given-names>L</given-names></name></person-group><article-title>Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases</article-title><source>Antimicrob Agents Chemother</source><year>2022</year><volume>66</volume><elocation-id>e0029022</elocation-id><pub-id pub-id-type="pmcid">PMC9211440</pub-id><pub-id pub-id-type="pmid">35652643</pub-id><pub-id pub-id-type="doi">10.1128/aac.00290-22</pub-id></element-citation></ref><ref id="R30"><label>(30)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>MD</given-names></name><name><surname>Peters</surname><given-names>KM</given-names></name><name><surname>Alvarez Fraga</surname><given-names>L</given-names></name><name><surname>Wallis</surname><given-names>SC</given-names></name><name><surname>Hancock</surname><given-names>SJ</given-names></name><name><surname>Nhu</surname><given-names>NTK</given-names></name><name><surname>Forde</surname><given-names>BM</given-names></name><name><surname>Bauer</surname><given-names>MJ</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Beatson</surname><given-names>SA</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Plasmid-Mediated Ciprofloxacin Resistance Imparts a Selective Advantage on Escherichia coli ST131</article-title><source>Antimicrob Agents Chemother</source><year>2022</year><volume>66</volume><elocation-id>e0214621</elocation-id><pub-id pub-id-type="pmcid">PMC8765324</pub-id><pub-id pub-id-type="pmid">34780264</pub-id><pub-id pub-id-type="doi">10.1128/AAC.02146-21</pub-id></element-citation></ref><ref id="R31"><label>(31)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moura</surname><given-names>A</given-names></name><name><surname>Soares</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Leitão</surname><given-names>N</given-names></name><name><surname>Henriques</surname><given-names>I</given-names></name><name><surname>Correia</surname><given-names>A</given-names></name></person-group><article-title>INTEGRALL: a database and search engine for integrons, integrases and gene cassettes</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>1096</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19228805</pub-id></element-citation></ref><ref id="R32"><label>(32)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smet</surname><given-names>A</given-names></name><name><surname>Van Nieuwerburgh</surname><given-names>F</given-names></name><name><surname>Vandekerckhove</surname><given-names>TT</given-names></name><name><surname>Martel</surname><given-names>A</given-names></name><name><surname>Deforce</surname><given-names>D</given-names></name><name><surname>Butaye</surname><given-names>P</given-names></name><name><surname>Haesebrouck</surname><given-names>F</given-names></name></person-group><article-title>Complete nucleotide sequence of CTX-M-15-plasmids from clinical Escherichia coli isolates: insertional events of transposons and insertion sequences</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><elocation-id>e11202</elocation-id><pub-id pub-id-type="pmcid">PMC2887853</pub-id><pub-id pub-id-type="pmid">20585456</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0011202</pub-id></element-citation></ref><ref id="R33"><label>(33)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>K</given-names></name><name><surname>Sime</surname><given-names>FB</given-names></name><name><surname>Wallis</surname><given-names>SC</given-names></name><name><surname>Bauer</surname><given-names>MJ</given-names></name><name><surname>Naicker</surname><given-names>S</given-names></name><name><surname>Won</surname><given-names>H</given-names></name><name><surname>Zowawi</surname><given-names>HM</given-names></name><name><surname>Choudhury</surname><given-names>MA</given-names></name><name><surname>Shirin</surname><given-names>T</given-names></name><name><surname>Habib</surname><given-names>ZH</given-names></name><name><surname>Harris</surname><given-names>PNA</given-names></name><etal/></person-group><article-title>Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model</article-title><source>Antimicrob Agents Chemother</source><year>2022</year><volume>66</volume><elocation-id>e0016222</elocation-id><pub-id pub-id-type="pmcid">PMC9487465</pub-id><pub-id pub-id-type="pmid">35924928</pub-id><pub-id pub-id-type="doi">10.1128/aac.00162-22</pub-id></element-citation></ref><ref id="R34"><label>(34)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>PNA</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><name><surname>Alenazi</surname><given-names>TH</given-names></name><name><surname>Arabi</surname><given-names>Y</given-names></name><name><surname>Falcone</surname><given-names>M</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Righi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2018</year><volume>320</volume><fpage>984</fpage><lpage>994</lpage><pub-id pub-id-type="pmcid">PMC6143100</pub-id><pub-id pub-id-type="pmid">30208454</pub-id><pub-id pub-id-type="doi">10.1001/jama.2018.12163</pub-id></element-citation></ref><ref id="R35"><label>(35)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoashi</surname><given-names>K</given-names></name><name><surname>Hayama</surname><given-names>B</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name><name><surname>Takehana</surname><given-names>K</given-names></name><name><surname>Enokida</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Ohkushi</surname><given-names>D</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>S</given-names></name></person-group><article-title>Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis</article-title><source>Microbiol Spectr</source><year>2022</year><volume>10</volume><elocation-id>e0220622</elocation-id><pub-id pub-id-type="pmcid">PMC9430612</pub-id><pub-id pub-id-type="pmid">35916524</pub-id><pub-id pub-id-type="doi">10.1128/spectrum.02206-22</pub-id></element-citation></ref><ref id="R36"><label>(36)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manuel</surname><given-names>C</given-names></name><name><surname>Maynard</surname><given-names>R</given-names></name><name><surname>Humphries</surname><given-names>RM</given-names></name></person-group><article-title>Evaluation of Piperacillin-Tazobactam ETEST for the Detection of OXA-1 Resistance Mechanism among Escherichia coli and Klebsiella pneumoniae</article-title><source>J Clin Microbiol</source><year>2022</year><volume>60</volume><elocation-id>e0143022</elocation-id><pub-id pub-id-type="pmcid">PMC9769679</pub-id><pub-id pub-id-type="pmid">36416539</pub-id><pub-id pub-id-type="doi">10.1128/jcm.01430-22</pub-id></element-citation></ref><ref id="R37"><label>(37)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>A</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Chatfield</surname><given-names>MD</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>De</surname><given-names>PP</given-names></name><name><surname>Lin</surname><given-names>RTP</given-names></name><name><surname>Chew</surname><given-names>KL</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study</article-title><source>Clin Infect Dis</source><year>2021</year><volume>73</volume><fpage>e3842</fpage><lpage>e3850</lpage><pub-id pub-id-type="pmid">33106863</pub-id></element-citation></ref><ref id="R38"><label>(38)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="pmcid">PMC4103590</pub-id><pub-id pub-id-type="pmid">24695404</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id></element-citation></ref><ref id="R39"><label>(39)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankevich</surname><given-names>A</given-names></name><name><surname>Nurk</surname><given-names>S</given-names></name><name><surname>Antipov</surname><given-names>D</given-names></name><name><surname>Gurevich</surname><given-names>AA</given-names></name><name><surname>Dvorkin</surname><given-names>M</given-names></name><name><surname>Kulikov</surname><given-names>AS</given-names></name><name><surname>Lesin</surname><given-names>VM</given-names></name><name><surname>Nikolenko</surname><given-names>SI</given-names></name><name><surname>Pham</surname><given-names>S</given-names></name><name><surname>Prjibelski</surname><given-names>AD</given-names></name><name><surname>Pyshkin</surname><given-names>AV</given-names></name><etal/></person-group><article-title>SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing</article-title><source>J Comput Biol</source><year>2012</year><volume>19</volume><fpage>455</fpage><lpage>477</lpage><pub-id pub-id-type="pmcid">PMC3342519</pub-id><pub-id pub-id-type="pmid">22506599</pub-id><pub-id pub-id-type="doi">10.1089/cmb.2012.0021</pub-id></element-citation></ref><ref id="R40"><label>(40)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seemann</surname><given-names>T</given-names></name></person-group><article-title>Prokka: rapid prokaryotic genome annotation</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2068</fpage><lpage>2069</lpage><pub-id pub-id-type="pmid">24642063</pub-id></element-citation></ref><ref id="R41"><label>(41)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zankari</surname><given-names>E</given-names></name><name><surname>Hasman</surname><given-names>H</given-names></name><name><surname>Cosentino</surname><given-names>S</given-names></name><name><surname>Vestergaard</surname><given-names>M</given-names></name><name><surname>Rasmussen</surname><given-names>S</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Aarestrup</surname><given-names>FM</given-names></name><name><surname>Larsen</surname><given-names>MV</given-names></name></person-group><article-title>Identification of acquired antimicrobial resistance genes</article-title><source>J Antimicrob Chemother</source><year>2012</year><volume>67</volume><fpage>2640</fpage><lpage>2644</lpage><pub-id pub-id-type="pmcid">PMC3468078</pub-id><pub-id pub-id-type="pmid">22782487</pub-id><pub-id pub-id-type="doi">10.1093/jac/dks261</pub-id></element-citation></ref><ref id="R42"><label>(42)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reding</surname><given-names>C</given-names></name><name><surname>Satapoomin</surname><given-names>N</given-names></name><name><surname>Avison</surname><given-names>MB</given-names></name></person-group><article-title>Hound: A novel tool for automated mapping of genotype to phenotype in bacterial genomes assembled <italic>de novo</italic></article-title><source>BioRxiv</source><year>2023</year><pub-id pub-id-type="doi">10.1101/2023.09.15.557405</pub-id></element-citation></ref><ref id="R43"><label>(43)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="pmcid">PMC2705234</pub-id><pub-id pub-id-type="pmid">19451168</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id></element-citation></ref><ref id="R44"><label>(44)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>A statistical framework for snp calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><fpage>2987</fpage><lpage>2993</lpage><pub-id pub-id-type="pmcid">PMC3198575</pub-id><pub-id pub-id-type="pmid">21903627</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btr509</pub-id></element-citation></ref><ref id="R45"><label>(45)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrow</surname><given-names>NS</given-names></name><name><surname>Alderton</surname><given-names>D</given-names></name><name><surname>Sainsbury</surname><given-names>S</given-names></name><name><surname>Nettleship</surname><given-names>J</given-names></name><name><surname>Assenberg</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Owens</surname><given-names>RJ</given-names></name></person-group><article-title>A versatile ligation-independent cloning method suitable for high-throughput expression screening applications</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>e45</fpage><pub-id pub-id-type="pmcid">PMC1874605</pub-id><pub-id pub-id-type="pmid">17317681</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkm047</pub-id></element-citation></ref><ref id="R46"><label>(46)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvopiña</surname><given-names>K</given-names></name><name><surname>Dulyayangkul</surname><given-names>P</given-names></name><name><surname>Heesom</surname><given-names>KJ</given-names></name><name><surname>Avison</surname><given-names>MB</given-names></name></person-group><article-title>TonB-dependent uptake of β-lactam antibiotics in the opportunistic human pathogen Stenotrophomonas maltophilia</article-title><source>Mol Microbiol</source><year>2020</year><volume>113</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">31773806</pub-id></element-citation></ref><ref id="R47"><label>(47)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takebayashi</surname><given-names>Y</given-names></name><name><surname>Wan Nur Ismah</surname><given-names>WAK</given-names></name><name><surname>Findlay</surname><given-names>J</given-names></name><name><surname>Heesom</surname><given-names>KJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>OM</given-names></name><name><surname>MacGowan</surname><given-names>AP</given-names></name><name><surname>Avison</surname><given-names>MB</given-names></name></person-group><article-title>Prediction of cephalosporin and carbapenem susceptibility in multi-drug resistant Gram-negative bacteria using liquid chromatography-tandem mass spectrometry</article-title><source>BioRxiv</source><year>2017</year><pub-id pub-id-type="doi">10.1101/138594</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Enzymatic assay illustrating ability of AAC(6’)-Ib-cr to modify both kanamycin B and amikacin.</title><p>Increasing concentrations of aminoglycoside substrates were incubated with 100 nM of purified enzyme and 0.1 mM acetyl-CoA for 1 h to allow enzymatic reaction to take place. Enzymatic activity was then measured by adding 2 mM DTNB and monitoring the absorbance at 412 nm of the by-product from an acetylation reaction. Enzymatic activity against kanamycin B as a known substrate, and amikacin as a suspected substrate, increased proportional to substrate concentration and above negative control. This suggests AAC(6’)-Ib-cr has the ability to modify amikacin. Negative controls contain no acetyl-coA and thus no measurable acetylation.</p></caption><graphic xlink:href="EMS192525-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Diagrammatic representation of In<italic>37</italic> and the derivative transposon.</title><p>The genes making up integron In<italic>37</italic> (A) and the derived transposon (B) are presented to scale. In<italic>37</italic> is a class 1 integron, with 5’ and 3’ conserved sequences (CS; orange), where the 5’CS encodes the integrase enzyme and an outward facing promoter that drives expression of the gene cassettes as a single transcript (orange arrow to P). In (B) the insertion sites of two copies of IS<italic>26</italic> are noted (red), where this generates a composite transposon including a hybrid IS<italic>26</italic>/In<italic>37</italic> promoter sequence (purple arrow to P), which mobilises <italic>aac(6’)-Ib-cr</italic> and <italic>bla</italic><sub>OXA-1</sub> (blue) but excludes the two distal gene cassettes from In<italic>37</italic> (green) with the <italic>catB3</italic> gene being truncated in the process (noted as <italic>catB3</italic>Δ).</p></caption><graphic xlink:href="EMS192525-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Relative AAC(6’)-lb-cr and OXA-1 protein abundance in transposon promoter mutants versus wild-type.</title><p>Bar charts show a relative protein abundance per gene copy number of (A) AAC(6’)-lb-cr and (B) OXA-1 with wild-type (WT) promoter and mutated (mutant) promoter. **** indicates <italic>p</italic>-value ≤ 0.0001 by unpaired t-test.</p></caption><graphic xlink:href="EMS192525-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Association between AAC(6’)-lb-cr abundance <italic>acc(6’)-lb-cr</italic> copy number and amikacin susceptibility.</title><p>(A) A linear correlation of AAC(6’)-lb-cr abundance and <italic>acc(6’)-lb-cr</italic> copy number, an outlier was shown in red (B). Association of amikacin susceptibility phenotype with (C) relative AAC(6’)-lb-cr abundance and (D) relative <italic>aac(6’)-lb-cr</italic> copy number. S, susceptible; R, resistant; **** indicates <italic>p</italic>-value ≤ 0.0001 and *** indicates <italic>p</italic>-value ≤ 0.001 by Mann-Whitney test.</p></caption><graphic xlink:href="EMS192525-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Associations between <italic>bla</italic><sub>OXA-1</sub> and <italic>aac(6’)-lb-cr</italic> copy number, OXA-1 abundance and Piperacillin/Tazobactam susceptibility.</title><p>A linear correlation of relative OXA-1 and (A) <italic>acc(6’)-lb-cr</italic> or (B) relative OXA-1 abundance where the outliner shows in red. Association of Piperacillin/Tazobactam susceptibility phenotype with (C) relative OXA-1 abundance and (D) relative OXA-1 gene copy number. S, susceptible; R, resistant; *** indicates <italic>p</italic>-value ≤ 0.001 and ** indicates <italic>p</italic>-value ≤ 0.01 by Mann-Whitney test.</p></caption><graphic xlink:href="EMS192525-f005"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Minimal inhibitory concentrations (MICs) of <italic>E. coli</italic> carrying <italic>aac(6’)-Ib-cr</italic> and variants against ciprofloxacin, kanamycin and amikacin.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="2">Strain</th><th align="left" valign="top" colspan="3">MIC (mg/L) of</th></tr><tr><th align="left" valign="top">Ciprofloxacin</th><th align="left" valign="top">Kanamycin</th><th align="left" valign="top">Amikacin</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>E. coli</italic> XL10 gold (plasmid only)</td><td align="left" valign="top">0.0625 (S)</td><td align="left" valign="top">4 (S)</td><td align="left" valign="top">2 (S)</td></tr><tr><td align="left" valign="top"><italic>E. coli</italic> XL10 gold (<italic>aac(6’)-Ib-cr</italic>)</td><td align="left" valign="top">0.25 (S)</td><td align="left" valign="top">&gt;128(R)</td><td align="left" valign="top">8 (S)</td></tr><tr><td align="left" valign="top"><italic>E. coli</italic> XL10 gold (<italic>aac(6’)-Ib-cr</italic> Y179D)</td><td align="left" valign="top">0.0625 (S)</td><td align="left" valign="top">&gt;128(R)</td><td align="left" valign="top">8 (S)</td></tr><tr><td align="left" valign="top"><italic>E. coli</italic> XL10 gold (<italic>aac(6’)-Ib-cr</italic> R102W)</td><td align="left" valign="top">0.125 (S)</td><td align="left" valign="top">&gt;128(R)</td><td align="left" valign="top">16 (R)</td></tr><tr><td align="left" valign="top"><italic>E. coli</italic> XL10 gold (<italic>aac(6’)-Ib-cr</italic> R102W, Y179D)</td><td align="left" valign="top">0.0625 (S)</td><td align="left" valign="top">&gt;128(R)</td><td align="left" valign="top">64 (R)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P34">S, susceptible; R, resistant</p></fn></table-wrap-foot></table-wrap></floats-group></article>